Variation in practice regarding pretreatment with dual antiplatelet therapy for patients with non–ST elevation myocardial infarction by Shafiq, Ali et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2016
Variation in practice regarding pretreatment with
dual antiplatelet therapy for patients with non–ST
elevation myocardial infarction
Ali Shafiq
University of Missouri-Kansas City
Javier Valle
University of Colorado
Jae-Sik Jang
Inje University
Mohammed Qintar
University of Missouri-Kansas City
Kensey Gosch
Saint Luke's Mid America Heart Institute
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Shafiq, Ali; Valle, Javier; Jang, Jae-Sik; Qintar, Mohammed; Gosch, Kensey; Cohen, David J.; Singh, Mandeep; Bach, Richard; and
Spertus, John A., ,"Variation in practice regarding pretreatment with dual antiplatelet therapy for patients with non–ST elevation
myocardial infarction." Journal of the American Heart Association.5,6. e003576. (2016).
http://digitalcommons.wustl.edu/open_access_pubs/5380
Authors
Ali Shafiq, Javier Valle, Jae-Sik Jang, Mohammed Qintar, Kensey Gosch, David J. Cohen, Mandeep Singh,
Richard Bach, and John A. Spertus
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/5380
Variation in Practice Regarding Pretreatment With Dual Antiplatelet
Therapy for Patients With Non–ST Elevation Myocardial Infarction
Ali Shaﬁq, MD, MSc; Javier Valle, MD; Jae-Sik Jang, MD; Mohammed Qintar, MD; Kensey Gosch, MS; David J. Cohen, MD, MSc;
Mandeep Singh, MD, MPH; Richard Bach, MD; John A. Spertus, MD, MPH
Background-—Despite guideline recommendations, a signiﬁcant number of patients with non–ST elevation myocardial infarction
(NSTEMI) do not receive dual antiplatelet therapy (DAPT) before angiography “pretreatment.” While there may be valid clinical
reasons to not pretreat, such as concern for bleeding or multivessel disease warranting coronary artery bypass graft surgery, the
degree of variability and factors associated with DAPT pretreatment are unknown.
Methods and Results-—From the multicenter TRIUMPH registry, 1632 NSTEMI patients were not taking DAPT on admission and
were included in the study cohort. Among the study patients, only 22% patients received DAPT pretreatment. A multivariable
logistic regression model showed that race other than white or black (odds ratio [OR] 0.41, 95% CI 0.21–0.83), hemoglobin level
(OR 1.18, 95% CI 1.08–1.29), patients’ bleeding risk (assessed with NCDR CathPCI Bleeding Risk Score) (OR 0.85, 95% CI 0.74–
0.99), and severe left ventricular dysfunction (OR 0.3, 95% CI 0.13–0.65) were the main predictors of pretreatment with DAPT,
whereas likelihood of needing coronary artery bypass graft surgery (GRACE prediction model) was not (OR 1.09, 95% CI 0.88–
1.35). Median ORs were calculated to assess variability of receiving DAPT pretreatment across sites after adjustment for patient
characteristics. Receiving DAPT pretreatment varied substantially across sites (range 0–100%, mean OR 3.94, P<0.0001).
Conclusions-—While deviating from guideline-recommended DAPT pretreatment in patients with NSTEMI was associated with
patient factors (eg, bleeding risk), marked variation was present across sites after accounting for patient-level characteristics. This
suggests that site-level interventions are needed to improve concordance with current guidelines. ( J Am Heart Assoc. 2016;5:
e003576 doi: 10.1161/JAHA.116.003576)
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A lthough early administration of dual antiplatelet therapy(DAPT) with aspirin and a platelet adenosine diphos-
phate receptor (P2Y-12) inhibitor is recommended by current
American Heart Association/American College of Cardiology
guidelines,1 recent data have demonstrated that up to half of
patients presenting with non–ST-elevation myocardial infarc-
tion (NSTEMI) do not receive DAPT before coronary
angiography (“pretreatment”).2,3 Deﬁning whether the varia-
tion in DAPT pretreatment is attributable to patient- or
provider-level factors can identify the importance and strategy
for quality improvement.
Many clinical considerations might support not using DAPT
pretreatment, such as concerns for increased bleeding risk
(eg, patients with low baseline hemoglobin, with low platelet
counts, or taking long-term anticoagulants) or the expectation
that the patients with NSTEMI might have underlying severe
coronary vessel disease requiring coronary artery bypass graft
surgery (CABG).4–9 Prediction models to detect the risk of
bleeding after percutaneous coronary intervention (PCI), as
well as to estimate the probability of undergoing CABG after a
NSTEMI,10–13 have been developed to support such decisions,
but whether avoiding DAPT pretreatment is associated with
patient-centered risks is unknown. Moreover, the variability
across hospitals in DAPT pretreatment for patients with
NSTEMI, after accounting for patient-level considerations in
its use can identify an important opportunity to increase the
consistency of guideline concordant care across centers.
We used the Translational Research Investigating Under-
lying Disparities in Acute Myocardial Infarction Patients’
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Health Status (TRIUMPH) registry of patients with acute
myocardial infarction (AMI) to examine practice pattern
variations of DAPT pretreatment in NSTEMI patients. To
illuminate patient-centered reasons for not using DAPT
pretreatment, we examined the association of patient-level
factors, including the recently validated14 Global Risk of Acute
Coronary Events (GRACE) model10 and the National Cardio-
vascular Data Registry (NCDR) CathPCI Bleeding Risk Score,15
with the use of DAPT before PCI. After adjusting for these
patient-level factors, we then examined site-level variations in
DAPT pretreatment.
Methods
Study Design
The study was designed as a retrospective analysis of patients
enrolled in the Translational Research Investigating Underlying
Disparities in Acute Myocardial Infarction Patients’ Health
Status (TRIUMPH) registry. Details regarding the TRIUMPH
registry have been described previously.16 In brief, TRIUMPH is
a large prospective multicenter registry that successively
enrolled patients across 24 sites with a diagnosis of AMI from
April 2005 through December 2008, a time when there was
broad consensus about the importance of DAPT pretreatment.
Patients 18 years and older who had elevated cardiac enzymes
(creatinine kinase-MB or troponin-I) on hospital admission and
characteristics of ischemia (chest pain or electrocardiographic
(ECG) abnormalities consistent with a diagnosis of AMI) were
eligible. Incarcerated patients were not eligible; patients were
also excluded if they refused to participate in the registry, were
unable to undergo informed consent, had prolonged transfer
periods from nonparticipating facilities (>24 hours), or did not
speak either English or Spanish. Trained study coordinators
abstracted data from the medical records and performed
baseline interviews within 24 to 72 hours of presentation to
assess patients’ demographic, clinical, socioeconomic,17,18
health, and psychological status. At each participating site,
institutional review boards approved the study protocol and
each patient provided signed informed consent.
Analytic Cohort
Given the focus of the guidelines on patients with NSTEMI, we
excluded patients with ST-elevation MI (STEMI) and those who
were already taking DAPT as outpatients before admission. At
the time of this study, DAPT consisted of aspirin and a P2Y-12
inhibitor (ie, clopidogrel or ticlopidine). We also excluded
patients enrolled at 2 sites in the TRIUMPH registry that did
not offer on-site CABG, where delays in CABG might be more
common and concerns about more extensive coronary
disease might be less relevant. The study cohort was then
assessed to determine which patients received pretreatment
with DAPT.
Statistical Analysis
Baseline characteristics of NSTEMI patients who did and did
not receive DAPT pretreatment were compared by using
Student t test for continuous variables and v2 tests for
categorical variables (Table). Based on literature review and
clinical criteria, we attempted to capture all patient and
clinical characteristics that we thought might be associated
with DAPT pretreatment. For example, we have previously
validated the GRACE model10 as the best method for
identifying the risk of patients for needing CABG in the
setting of NSTEMI.14 Thus, to best capture this important
reason for not pretreating with DAPT before angiography, we
calculated the risk score by using the GRACE model for each
patient on the basis of their sex; history of CABG, angina,
congestive heart failure, dyslipidemia, hypertension, atrial
ﬁbrillation, and diabetes; and ECG ﬁndings. To assess whether
the patients’ risk of bleeding was associated with avoiding
DAPT pretreatment, we collected data regarding patients
taking coumadin or any other oral anticoagulants on admis-
sion and their preprocedural platelet counts. We also
calculated each patient’s NCDR CathPCI Bleeding Risk
Score.15 Finally, we collected some additional variables based
on clinical judgment that we thought might be associated with
DAPT pretreatment; such as race, history of smoking, stroke/
transient ischemic attack, peripheral arterial disease, chronic
lung disease, family history of coronary artery disease, and
baseline left ventricular (LV) function.
We then used hierarchical logistic regression models, with
site-centered covariates, to assess whether our collected
variables had a signiﬁcant association with DAPT pretreat-
ment. The raw rates of DAPT pretreatment were assessed
among all study sites. To assess the extent of variability in
DAPT pretreatment across sites, we calculated the median
odds ratios (MOR). The MOR estimates the difference in
likelihood of receiving DAPT pretreatment at one random
study site versus the other after accounting for patient-level
characteristics.19,20 SAS version 9.4 was used to perform all
analyses. All analyses were prespeciﬁed, and a 2-sided P
value <0.05 denoted statistical signiﬁcance.
A majority of patients (93%) were not missing any covariate
information, with 2% missing 1 value and 5% missing ≥2. The
highest missing rate for any single variable was 4.8% (GRACE
CABG Risk Score), followed by smoking status, which was
missing in 0.6% of patients. To correct for any biases because
of the small number of missing covariates, data were imputed
by using an imputation model that contained all of the
variables from the multivariable model (IVEware; Institute for
Social Research).21 Table S1 shows no signiﬁcant differences
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when comparing the output of logistic regression models with
and without missing data.
Results
Study Population
There were 4340 patients with an AMI enrolled in the TRIUMPH
registry. We excluded patients with STEMI (n=1860), those who
were already taking DAPT on admission (n=387), and patients
who did not have information regarding their pretreatment with
DAPT (n=390). We further excluded 71 patients who were
enrolled at 2 sites in the TRIUMPH registry that did not perform
on-site CABG. The ﬁnal study cohort consisted of 1632 NSTEMI
patients across 22 study sites (Figure 1).
Unadjusted Association of Patient Factors With
DAPT Pretreatment
Among the study cohort, 359 (22%) patients received
pretreatment with DAPT. Table shows the overall demo-
graphic and clinical characteristics of patients who did and did
not receive pretreatment with DAPT. Patients in the pretreat-
ment group were younger and more likely to be male and
white, with a lower prevalence of prior CABG, MI, heart failure,
hypertension, and diabetes. The pretreatment group was also
more likely to have a higher hemoglobin level, to not be taking
warfarin, and to have normal LV systolic function. Paradox-
ically, the likelihood of having multivessel coronary disease
Table. Baseline Characteristics of NSTEMI Patients
Undergoing DAPT Pretreatment Versus No Pretreatment
Variable
DAPT
Pretreatment,
n=359
No
Pretreatment,
n=1273 P Value
Mean age, y 58.312.4 60.512.7 0.003
Male 69.6% 62.7% 0.015
Race <0.001
White/Caucasian 72.8% 58.8%
Black/African American 22.8% 35.6%
Other 4.5% 5.7%
Smoking status 0.669
Current (<30 d) 37.3% 35.4%
Former (>30 d) 32.6% 32.1%
Never (<100 d) 30.1% 32.5%
Medical history
Prior angina 12.0% 13.1% 0.569
Prior CABG 6.4% 12.6% 0.001
Prior MI 15.9% 22.7% 0.005
Prior PCI 16.7% 14.8% 0.385
Prior CVA or TIA 5.0% 8.3% 0.036
Chronic kidney disease 5.8% 9.8% 0.02
Chronic heart failure 2.5% 13.7% <0.001
Peripheral vascular
disease
3.9% 4.8% 0.476
Chronic lung disease 5.3% 10.9% 0.001
Hypertension 66.0% 73.4% 0.006
Diabetes 28.7% 34.9% 0.028
Hospital presentation characteristics
Killip Class <0.001
I 93.5% 84.5%
II 5.1% 12.5%
III 1.4% 2.1%
IV 0.0% 0.9%
LV systolic function <0.001
Normal 80.7% 64.3%
Mild 10.9% 15.7%
Moderate 5.9% 9.3%
Severe 2.5% 10.7%
ECG findings
ST depression 23.7% 26.6% 0.278
ST elevation 9.4% 11.6% 0.265
LBBB 2.5% 5.5% 0.02
Family history of CAD 75.8% 71.0% 0.075
Continued
Table. Continued
Variable
DAPT
Pretreatment,
n=359
No
Pretreatment,
n=1273 P Value
Medications on arrival or before cardiac catheterization
Warfarin 2.5% 7.6% <0.001
GP IIb/IIIa inhibitors 41.2% 28.5% <0.001
Baseline laboratory values
Initial hemoglobin, g/dL 14.31.7 13.52.2 <0.001
Initial platelet count 250.677.2 253.486.5 0.583
Risk scores
GRACE CABG Risk Score 10.01.6 9.71.8 0.002
NCDR CathPCI Bleeding
Risk Score
50.614.9 55.218.3 <0.001
Data are reported as meanSD or %. CABG indicates coronary artery bypass graft
surgery; CAD, coronary artery disease; CVA, cerebrovascular accident; DAPT, dual
antiplatelet therapy; ECG, electrocardiogram; GP IIb/IIIa, glycoprotein IIb/IIIa; GRACE,
Global Risk of Acute Coronary Events; LBBB, left bundle-branch block; LV, left ventricular;
MI, myocardial infarction; NCDR, National Cardiovascular Data Registry; NSTEMI, non–ST
elevation myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient
ischemic attack.
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requiring CABG, the GRACE CABG Risk Scores, were slightly
higher for those pretreated with DAPT compared with those
who were not (10.01.6 versus 9.71.8, P=0.002), but the
risk of bleeding, as assessed with NCDR CathPCI Bleeding
Risk Scores, was lower in those pretreated with DAPT
(50.614.9 versus 55.218.3, P<0.001).
Adjusted Association of Patient Factors With
DAPT Pretreatment
Independent predictors of pretreatment with DAPT included
higher hemoglobin levels (odds ratio [OR] per 1 g/dL 1.18,
95% CI 1.08–1.29 per 1 g/dL), race other than white or black
(OR 0.41, 95% CI 0.21–0.83), and mild (OR 0.55, 95% CI
0.36–0.84), moderate (OR 0.60, 95% CI 0.35–1.03), and
severe LV dysfunction (OR 0.3, 95% CI 0.13–0.65). Patients’
bleeding risk (assessed with NCDR CathPCI Bleeding Risk
Scores for an increase by 10 points) (OR 0.85, 95% CI 0.74–
0.99) was also signiﬁcantly associated with DAPT pretreat-
ment. The patients’ risk for needing CABG (as assessed with
the GRACE CABG Risk Score for 1-point increase in total
score [OR 1.09, 95% CI 0.88–1.35]) was not associated with
DAPT pretreatment. The main predictors in the regression
model are shown in Figure 2. The ﬁnal model had a c-statistic
of 0.83.
Variability in DAPT Pretreatment Across Centers
Marked variability in DAPT pretreatment was observed across
sites ranging, from 0% to 100% (Figure 3). After adjusting for
patient characteristics in a hierarchical model, the MOR was
3.94 (95% CI 2.04–6.09) with P<0.0001. This suggests an
almost 4-fold mean variation in the likelihood that a patient
with NSTEMI presenting at 1 random site in the TRIUMPH
study would be treated with DAPT before PCI versus another.
Discussion
As the United States transitions to value-based healthcare
reimbursement, the importance of delivering consistent,
guideline-concordant care grows ever more important and
insights into the source of treatment variability become a
priority. In this multicenter registry of patients with NSTEMI,
we found marked variability in the rates of DAPT pretreatment
across sites, ranging from 0% to 100%. Importantly, we
observed an independent association between a number of
Figure 1. Flow chart of patient selection. CABG indicates coro-
nary artery bypass graft surgery; DAPT, dual antiplatelet therapy;
STEMI, ST elevation myocardial infarction; TRIUMPH, Translational
Research Investigating Underlying Disparities in Acute Myocardial
Infarction Patients’ Health Status.
Figure 2. Patient predictors of dual antiplatelet therapy (DAPT)
pretreatment. Forest plot depicting the odds ratios of patient level
that are associated with odds of receiving DAPT treatment. CABG
indicates coronary artery bypass graft surgery; GRACE, Global Risk
of Acute Coronary Events; NCDR, National Cardiovascular Data
Registry; TRIUMPH, Translational Research Investigating Underlying
Disparities in Acute Myocardial Infarction Patients’ Health Status.
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variables suggesting increased risk from DAPT and the
avoidance of DAPT pretreatment, such as lower hemoglobin
levels, taking anticoagulants on admission, and bleeding risk.
However, we found no independent association between
patients’ likelihood of needing CABG and the avoidance of
DAPT pretreatment. After adjusting for all patient character-
istics independently associated with DAPT pretreatment, we
still found marked variability in treatment across hospitals. On
average, a given patient with NSTEMI presenting at one
TRIUMPH site versus another would be almost 4 times more
likely to be pretreated with DAPT. This large degree of
variation across sites suggests that site-level interventions are
needed to improve the consistency of DAPT pretreatment for
patients with NSTEMI undergoing PCI across hospitals.
Our work expands on the current understanding of practice
patterns surrounding pretreatment with DAPT. We found that
the majority of patients with NSTEMI in our study cohort did
not receive DAPT pretreatment, which is similar to previous
studies.2,3 A retrospective analysis published in 2010,
assessing 6253 patients who underwent PCI, showed that
56% of patients with NSTEMI or unstable angina did not
receive pretreatment with DAPT.22 Also, in a randomized
controlled trial of 9492 patients with high-risk acute coronary
syndromes, conducted in 29 countries, Giugliano et al
showed that the rate of intended early use of clopidogrel as
a part of DAPT was lower in North America than elsewhere
(50.8% versus 85.8%).23 The most common reasons cited by
previous studies for physicians not pretreating patients with
DAPT are the risk of increased bleeding and the likelihood that
patients may need to undergo CABG and will be susceptible to
prolonged hospital stays.4 In our study, we studied in detail
how strongly the risk of bleeding or other clinical factors may
be associated with DAPT pretreatment. Our analyses showed
that patients taking oral anticoagulants or who had high
NCDR CathPCI Bleeding Risk Scores with any degree of LV
dysfunction were less likely to receive DAPT pretreatment. On
the other hand, patients with a higher hemoglobin level had
higher odds of being pretreated. These observations suggest
that providers may be rationally considering the risk of
bleeding as well as how stable patients are with regard to
their cardiac function when deciding whether to pretreat
patients with DAPT. Our study further showed that patients
who were not black or white were less likely to receive DAPT.
A potential reason for this is that despite being underrepre-
sented in major clinical trials, there is evidence to suggest
that minority groups, especially Asian patients, are more
prone to bleeding complications following PCI, compared with
white patients.24 Therefore, providers might be considering
this risk of bleeding in these minority patients and be less
likely to pretreat them with DAPT. However, further research
is needed to evaluate this relationship. More importantly, we
found that DAPT pretreatment was not signiﬁcantly associ-
ated with the patients’ GRACE model risk score, leading us to
believe that providers may not be considering the risk of
CABG as an important factor to give or delay DAPT. The
signiﬁcant variability in rates of pretreatment with DAPT
across facilities that was present even after accounting for
patient-level factors shows that providers are not using a
standardized approach to risk-stratify patients for purposes of
administering or delaying DAPT pretreatment.
American Heart Association/American College of Cardiol-
ogy and European Society of Cardiology guidelines recom-
mend initiating DAPT at the earliest time after presentation to
the hospital and before angiography (pretreatment).1,24 These
recommendations are mainly based on evidence from the
Percutaneous Coronary Intervention-Clopidogrel in Unstable
angina to prevent Recurrent Events (PCI-CURE)5 and the
Clopidogrel for the Reduction of Events During Observation
(CREDO) trials,25 which were conducted more than a decade
ago and may not represent contemporary practice trends. In
these studies, most of the patients had their PCIs postponed
for up to several days after pretreatment, whereas current
practice often leads to invasive treatment within hours of ﬁrst
medical contact. Also, recent studies suggest that DAPT
pretreatment may not necessarily improve cardiovascular
outcomes.17,19 A recent meta-analysis showed that 32 383
NSTEMI patients who received pretreatment with aspirin and
clopidogrel did not have a signiﬁcantly lower risk of mortal-
ity.19 Another randomized trial (the Comparison of Prasugrel
at the Time of PCI or Pretreatment at the Time of Diagnosis in
Patients with Non-ST Elevation Myocardial Infarction
[ACCOAST]) enrolled 4033 NSTEMI patients and found that
Figure 3. Graph of site-level variation for receiving dual anti-
platelet therapy (DAPT) pretreatment. The x-axis shows sites that
were included in the TRIUMPH registry from 1 to 23. The y-axis
shows percentages of patients as a function of each site that
received DAPT pretreatment. TRIUMPH indicates Translational
Research Investigating Underlying Disparities in Acute Myocardial
Infarction Patients’ Health Status.
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pretreatment with prasugrel (a more potent antiplatelet agent
than clopidogrel) did not decrease adverse cardiac outcomes
but rather was associated with increased bleeding.18 There-
fore, if patient-centered reasons (like risk of bleeding) are the
cause of the low DAPT pretreatment, then deviating from
guidelines may not necessarily provide poor care, especially in
light of new emerging evidence.26 In contrast, if site-level
variability accounts for the use of DAPT before coronary
angiography independent of patient-level factors, then it
would underscore the importance of quality improvement
efforts to improve guideline concordance and improve the
consistency of care.27 Previously proposed models that either
predict the likelihood for CABG or estimate the bleeding risk
for patients presenting with NSTEMI may not be perfect.10–14
However, these prediction models could provide clinicians
with evidence-based guidance for the selection of DAPT
pretreatment, thereby providing a more standardized
approach to treating patients with NSTEMI, potentially
reducing practice variations and helping to increase adher-
ence to the guidelines.
Our ﬁndings should be considered in the context of several
potential limitations. At the time of our study (2005–2008),
there was little controversy regarding giving DAPT pretreat-
ment. However, the addition of newer P2Y-12 inhibitors with a
more rapid onset of action and conﬂicting data, such as those
from ACCOAST, may suggest that pretreatment is less
important now than at the time of this study. Nevertheless,
insights separating patient-level from site-level variability are
important and whatever practice patterns are eventually
adopted would likely require site-level interventions to support
the consistency of care across hospitals. In addition, although
we attempted to look at a comprehensive list of patient-level
factors that were potentially associated with DAPT pretreat-
ment, we could have missed important variables, which could
have inﬂuenced/confounded our results, but our logistic
regression model had a good discrimination with c-statistic of
0.83 providing us with reasonable conﬁdence in the results.
Also, glycoprotein IIb/IIIa inhibitors are a form of antiplatelet
therapy that can also be administered upstream of angiography
and inﬂuence DAPT pretreatment, but as we did not have data
regarding the exact time of administration of thesemedications
(whether patients received them before or after getting DAPT),
we did not include them as a “predictor variable” in our logistic
regression analyses. Finally, we only explored practice trends
of DAPT pretreatment and did not examine outcomes, as
previous large-scale trials have already explored this.
In our multicenter MI registry, less than one-fourth of
NSTEMI patients were pretreated with DAPT, and while
patient characteristics associated with increased bleeding risk
were also associated with less DAPT pretreatment, there
remained marked variation across sites even after adjusting
for these patient factors. These ﬁndings suggest that the use
of DAPT before angiography in NSTEMI patients is more
inﬂuenced by site-level protocols, rather than personalized
care to individual patients. Efforts to improve the quality of
DAPT pretreatment should focus on site-level interventions,
which seem more important than any patient-level consider-
ations in current practice.
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SUPPLEMENTAL MATERIAL 
 
 
 
 
Table S1. Comparison of Logistic Regression Models with and without Missing Data 
Variables 
Model with  
Missing Data 
O.R (95% C.I) 
Model with 
 Imputed Data 
O.R (95% C.I) 
Age (yrs) 1.00 (0.92-1.09) 1.01 (0.93-1.10) 
Male versus female 0.67 (0.40-1.11) 0.68 (0.41-1.11) 
Race (reference = white)     Black 1.02 (0.68-1.52) 1.05 (0.71-1.55) 
  Other 0.45 (0.22-0.91) 0.41 (0.20-0.83) 
Angina 1.12 (0.58-2.16) 1.00 (0.53-1.88) 
Prior bypass graft surgery 0.79 (0.33-1.88) 0.89 (0.39-2.03) 
Prior AMI 0.86 (0.55-1.36) 0.86 (0.55-1.32) 
Prior PCI 1.00 (0.62-1.61) 1.01 (0.63-1.60) 
CVA/TIA 0.93 (0.50-1.71) 0.95 (0.52-1.72) 
Chronic kidney disease 1.37 (0.73-2.58) 1.44 (0.77-2.6) 
Congestive heart failure 0.51 (0.22-1.15) 0.51 (0.22-1.14) 
Peripheral vascular disease 1.05 (0.51-2.16) 0.98 (0.48-1.99) 
Chronic lung disease 0.73 (0.40-1.33) 0.73 (0.40-1.31) 
Hypertension 1.02 (0.67-1.54) 0.94 (0.63-1.40) 
Diabetes 0.91 (0.59-1.39) 0.86 (0.57-1.30) 
Family history of CAD 1.21 (0.86-1.70) 1.18 (0.85-1.64) 
LV Function (reference=normal)   Mild 0.59 (0.38-0.90) 0.55 (0.36-0.84) 
Moderate 0.59 (0.34-1.05) 0.60 (0.34-1.03) 
Severe 0.36 (0.15-0.83) 0.29 (0.13-0.65) 
Smoking status ( reference=current smoker)     Former 1.09 (0.75-1.59) 1.08 (0.75-1.56) 
  Never  0.98 (0.68-1.42) 0.96 (0.67-1.38) 
Warfarin 0.56 (0.24-1.32) 0.58 (0.26-1.29) 
Hemoglobin 1.19 (1.09-1.31) 1.18 (1.08-1.29) 
Platelet count (per 25 units) 0.97 (0.93-1.02) 0.98 (0.94-1.03) 
EKG     ST depression 0.95 (0.67-1.36) 0.88 (0.62-1.24) 
  ST elevation 0.92 (0.46-1.83) 1.06 (0.55-2.06) 
NCDR Bleeding Risk Score (per 10 points 
 
0.85 (0.73-0.99) 0.85 (0.73-0.98) 
GRACE CABG Score (per 1 point increase) 1.04 (0.83-1.30) 1.08 (0.87-1.34) 
AMI, acute myocardial infarction; CAD, coronary artery disease; CVA, cerebrovascular disease; LV, left 
ventricular; NCDR, National Cardiovascular Data Registry; PCI, percutaneous coronary intervention;  
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